Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Blue cornmeal contains 9,642-12,182 mg CGE/kg of anthocyanins, primarily cyanidin derivatives comprising 98% of total anthocyanin content. These compounds demonstrate antioxidant, ACE-inhibitory, and antiproliferative mechanisms through multiple molecular pathways in laboratory studies.
Reported Benefits (Provisional)
Origin & History
Blue Cornmeal (Zea mays L. 'Blue') is a distinct variety of maize, traditionally cultivated by Indigenous peoples across Central and North America. Its deep blue-purple hue signifies a rich concentration of beneficial phytochemicals. This ancient grain offers a unique nutritional profile, making it valuable for functional nutrition.
Research Narrative (Provisional)
Preliminary in vitro and animal studies indicate Blue Cornmeal's anthocyanins possess significant antioxidant and anti-inflammatory properties. Human dietary studies are emerging, focusing on its impact on cardiovascular markers and glycemic response. Further clinical trials are needed to fully elucidate its broad health benefits.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Complex Carbohydrates - Dietary Fiber - Vitamin A - Zinc - Selenium - Anthocyanins (e.g., cyanidin-3-glucoside) - Lutein
Reported Mechanism (Provisional)
Cyanidin-based anthocyanins provide the primary bioactive effects, demonstrating 94.3% ACE-inhibitory activity for blood pressure regulation and 18.45% antioxidant activity after germination. The fat fraction containing linoleic and oleic acids shows the strongest antidiabetic activity through glucose metabolism modulation. Bioactive peptides from blue corn gluten exhibit anti-hypertensive effects by inhibiting angiotensin-converting enzyme.
Clinical Narrative (Provisional)
Current evidence consists primarily of in vitro and animal studies rather than human clinical trials. Laboratory studies show antiproliferative effects against cancer cell lines (HepG2, H-460, MCF-7, PC-3) at 250-1,000 µg/mL concentrations, with nixtamalized forms requiring lower effective doses. Mouse studies demonstrate bioactive peptides reach maximum serum ACE-inhibitory capacity of 59% within 15 minutes of ingestion. Human clinical trials are needed to establish therapeutic efficacy and optimal dosing protocols.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.